Introduction from Drug peptide supply about:Liraglutide/204656-20-2
| English name | Liraglutide |
| Chinese name | 利拉鲁肽 |
| CAS NO | 204656-20-2 |
| Peptide sequence | His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(palm-gama-Glu)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly |
| Molecular formula | C172H265N43O51 |
| Molecular weight | 3751.202 |
| storage temperature | 2-8℃ |
| purity | ≥98% |
| Package | 1mg;5mg;10mg;50mg;100mg,1g or according to customer’s detail requirement. |
| Product English synonyms | Liraglutidum;Liraglutidum [inn-latin];N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glp-1-(7-37)-peptide |
Overview of Liraglutide
Liraglutide is a clear, colorless solution. The dosage form is subcutaneous injection. After more than 10 years of research and development, liraglutide has many effects such as promoting islet cell regeneration, lowering blood sugar, reducing body weight, and protecting the cardiovascular system. As a supplement to diet control and physical activity. Liraglutide is an acylated human glucagon-like peptide-1 (GLP-1) receptor agonist with 97% amino acid sequence homology to human endogenous GLP-1 (7-37), retaining It has all the biological activities of GLP-1 and has GLP-1 receptor agonism. Through the expression of recombinant DNA in Saccharomyces cerevisiae, its molecular structure has only one amino acid difference from the natural GLP-1 molecule. The structure only modifies GLP-1 in the following two parts: that is, the 34th lysine is replaced by arginine. Acid substitution, additionally adding a glutamate-mediated 16-carbon palmitoyl fatty acid side chain at lysine 26.
The mechanism of action of liraglutide
Liraglutide, like endogenous GLP-1, binds to and activates the GLP-1 receptor—a cell surface receptor that activates adenylate cyclase through the coupling of excitatory G-protein Gs. Endogenous GLP-1 has a half-life of 1.5–2 min and is easily degraded by two ubiquitous endogenous enzymes, dipeptidyl peptidase 4 (DPP-4) and neutral endopeptidase (NEP). Compared with native GLP-1, liraglutide is relatively stable, with a plasma half-life of 13h after subcutaneous administration. This half-life change is attributed to the structural modification of liraglutide. Due to the presence of the fatty acid side chain, on the one hand, the hydrophobic self-association of palmitic acid forms a heptamer, which slows the absorption at the subcutaneous injection site; on the other hand, the absorption After entering the blood, it binds to plasma albumin and increases to form a slow-release reservoir, temporarily avoiding contact with endogenous enzymes and slowing down the release, prolonging the absorption and distribution time in the body, and the half-life is significantly longer than that of natural GLP-1.
Liraglutide has the following pharmacological effects:
Protective effect on pancreatic beta cells
The effect of reducing body mass
Cardiovascular effects of liraglutide
Protective effect on the liver
Therapeutic effect on Alzheimer’s disease (AD)
How to buy Liraglutide in the U. S.
Peptide supplier Remetide specializes in the production and sales of peptides in the USA. Professional Drug peptide R&D. Professional drug peptide seller. Feel free to contact us if you have any questions or inquiries about Peptides.
Hot line:+19498788363
Wechat:americhina
Email:amin@remetide.com